Cargando…
Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies
Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical ou...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763291/ https://www.ncbi.nlm.nih.gov/pubmed/33322093 http://dx.doi.org/10.3390/jcm9124028 |
_version_ | 1783627983674671104 |
---|---|
author | Meseguer, Elena Diallo, Devy Labreuche, Julien Charles, Hugo Delbosc, Sandrine Mangin, Gabrielle Monteiro Tavares, Linsay Caligiuri, Giuseppina Nicoletti, Antonino Amarenco, Pierre |
author_facet | Meseguer, Elena Diallo, Devy Labreuche, Julien Charles, Hugo Delbosc, Sandrine Mangin, Gabrielle Monteiro Tavares, Linsay Caligiuri, Giuseppina Nicoletti, Antonino Amarenco, Pierre |
author_sort | Meseguer, Elena |
collection | PubMed |
description | Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical outcomes in 153 stroke patients treated by thrombolysis and mechanical endovascular treatment (MET). Biomarkers were related to hemostasis (u-plasminogen activator/urokinase (uPA/urokinase), serpin E1/PAI-1, serpin C1/antithrombin-III, kallikrein 6/neurosin, alpha 2-macroglobulin), inflammation[myloperoxidase (MPO), chemokine ligand 2/monocyte chemoattractant protein-1 chemokine (CCL2/MCP-1), adiponectin, resistin, cell-free DNA (cDNA), CD40 Ligand (CD40L)], endothelium activation (Vascular cell adhesion protein 1 (VCAM-1) intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule 1 (CD31/PECAM-1)], and tissue remodeling (total cathepsin S, osteopontin, cystatin C, neuropilin-1, matrix metallopeptidase 2 (MMP-2), matrix metallopeptidase 3 (MMP-3), matrix metallopeptidase 9 (MMP-9), matrix metallopeptidase 13 (MMP-13)]. Correlations between their levels and excellent neurological improvement (ENI) at 24 h and good outcomes (mRS 0–2) at three months were tested. Osteopontin and favorable outcomes reached the significance level (p = 0.008); the adjusted OR per SD increase in log-transformed osteopontin was 0.34 (95%CI, 0.18–0.62). The relationship between total cathepsin S and MPO with ENI, was borderline of significance (p = 0.064); the adjusted OR per SD increase in log-transformed of total cathepsin S and MPO was 0.54 (95%CI, 0.35–0.81) and 0.51 (95%CI, 0.32–0.80), respectively. In conclusion, osteopontin levels predicted three-month favorable outcomes, supporting the use of this biomarker as a complement of clinical and radiological parameters for predicting stroke prognosis. |
format | Online Article Text |
id | pubmed-7763291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77632912020-12-27 Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies Meseguer, Elena Diallo, Devy Labreuche, Julien Charles, Hugo Delbosc, Sandrine Mangin, Gabrielle Monteiro Tavares, Linsay Caligiuri, Giuseppina Nicoletti, Antonino Amarenco, Pierre J Clin Med Article Establishing a prognosis at hospital admission after stroke is a major challenge. Inflammatory processes, hemostasis, vascular injury, and tissue remodeling are all involved in the early response to stroke. This study analyzes whether 22 selected biomarkers, sampled at admission, predict clinical outcomes in 153 stroke patients treated by thrombolysis and mechanical endovascular treatment (MET). Biomarkers were related to hemostasis (u-plasminogen activator/urokinase (uPA/urokinase), serpin E1/PAI-1, serpin C1/antithrombin-III, kallikrein 6/neurosin, alpha 2-macroglobulin), inflammation[myloperoxidase (MPO), chemokine ligand 2/monocyte chemoattractant protein-1 chemokine (CCL2/MCP-1), adiponectin, resistin, cell-free DNA (cDNA), CD40 Ligand (CD40L)], endothelium activation (Vascular cell adhesion protein 1 (VCAM-1) intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule 1 (CD31/PECAM-1)], and tissue remodeling (total cathepsin S, osteopontin, cystatin C, neuropilin-1, matrix metallopeptidase 2 (MMP-2), matrix metallopeptidase 3 (MMP-3), matrix metallopeptidase 9 (MMP-9), matrix metallopeptidase 13 (MMP-13)]. Correlations between their levels and excellent neurological improvement (ENI) at 24 h and good outcomes (mRS 0–2) at three months were tested. Osteopontin and favorable outcomes reached the significance level (p = 0.008); the adjusted OR per SD increase in log-transformed osteopontin was 0.34 (95%CI, 0.18–0.62). The relationship between total cathepsin S and MPO with ENI, was borderline of significance (p = 0.064); the adjusted OR per SD increase in log-transformed of total cathepsin S and MPO was 0.54 (95%CI, 0.35–0.81) and 0.51 (95%CI, 0.32–0.80), respectively. In conclusion, osteopontin levels predicted three-month favorable outcomes, supporting the use of this biomarker as a complement of clinical and radiological parameters for predicting stroke prognosis. MDPI 2020-12-13 /pmc/articles/PMC7763291/ /pubmed/33322093 http://dx.doi.org/10.3390/jcm9124028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Meseguer, Elena Diallo, Devy Labreuche, Julien Charles, Hugo Delbosc, Sandrine Mangin, Gabrielle Monteiro Tavares, Linsay Caligiuri, Giuseppina Nicoletti, Antonino Amarenco, Pierre Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title | Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title_full | Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title_fullStr | Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title_full_unstemmed | Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title_short | Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies |
title_sort | osteopontin predicts three-month outcome in stroke patients treated by reperfusion therapies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7763291/ https://www.ncbi.nlm.nih.gov/pubmed/33322093 http://dx.doi.org/10.3390/jcm9124028 |
work_keys_str_mv | AT meseguerelena osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT diallodevy osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT labreuchejulien osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT charleshugo osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT delboscsandrine osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT mangingabrielle osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT monteirotavareslinsay osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT caligiurigiuseppina osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT nicolettiantonino osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies AT amarencopierre osteopontinpredictsthreemonthoutcomeinstrokepatientstreatedbyreperfusiontherapies |